logo

For the Inventor, By the Inventor

Englewood, NJ, United States of America

Michael M Goldberg

This inventor holds 14 USPTO granted patents, plus 1 CIPO patent, primarily in Oral Drug Delivery. Top assignees: Emisphere Technologies, Inc., Novartis Ag, Other. Active years: 1991-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael M Goldberg. Retrieved from https://idiyas.com/inventor/michael-m-goldberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14

% Patents Active = 35.7

 

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 188(Granted Patents)


Location History:

  • Cherry Hill, NJ (US) (1991)
  • Englewood, NJ (US) (2008 - 2015)
  • Tarrytown, NY (US) (2008 - 2016)

Company Filing History:

goldMedal12 out of 183 
 
Emisphere Technologies, Inc.
 patents
silverMedal5 out of 3,979 
 
Novartis Ag
 patents
bronzeMedal1 out of 834,708 
Other
 patents
where one patent can have more than one assignee

Years Active: 1991-2016

Loading Chart...
Loading Chart...
Areas of Expertise:
Cromolyn Formulations
Intraoral Dosage Forms
Glucagon
Oral Insulin Therapies
Active Agent Delivery
Disodium Salts
Monohydrates
Ethanol Solvates
Oral Administration
Night-Time Therapy
14 patents (USPTO):Explore Patents
1. 9498487 - Topical cromolyn formulations (2016-11-22),
2. 8975227 - Intraoral dosage forms of glucagon (2015-03-10),
3. 8962554 - Oral insulin therapies and protocol (2015-02-24),
4. 8729016 - Oral insulin therapies and protocol (2014-05-20),
5. 8658695 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents (2014-02-25),
6. 8513300 - Formulations for oral administration of cromolyn sodium (2013-08-20),
7. 8324156 - Oral insulin therapies and protocol (2012-12-04),
8. 8207227 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents (2012-06-26),
9. 8003697 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents (2011-08-23),
10. 7659311 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents (2010-02-09),
11. 7429564 - Oral insulin therapy (2008-09-30),
12. 7384982 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents (2008-06-10),
13. 7384914 - Night-time oral insulin therapy (2008-06-10),
14. 5060678 - Artificial nail and implantation techniques (1991-10-29),

Title: The Innovative Journey of Michael M Goldberg

Introduction: Michael M Goldberg, a pioneering inventor based in Englewood, NJ (US), has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Michael M Goldberg holds several patents in various technological domains, showcasing his versatility and ingenuity in creating novel solutions to complex problems.

Career Highlights: Throughout his illustrious career, Michael M Goldberg has been at the forefront of innovation, consistently pushing the boundaries of what is possible in the tech industry. His dedication to research and development has led to the creation of cutting-edge technologies that have revolutionized the way we live and work.

Collaborations: Michael M Goldberg has collaborated with leading tech companies, research institutions, and universities to further his research and bring his inventions to life. His collaborative spirit and passion for innovation have been instrumental in the success of his projects.

Conclusion: In conclusion, Michael M Goldberg's innovative spirit, coupled with his relentless drive to create, has cemented his legacy as a trailblazing inventor in the world of technology. His contributions have not only shaped the industry but have also inspired future generations of inventors to dream big and think outside the box.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…